We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Trial of Drainage With or Without Bleomycin Instillation for Malignant Pericardial Effusion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00132613
Recruitment Status : Completed
First Posted : August 22, 2005
Last Update Posted : September 22, 2016
Information provided by:

August 19, 2005
August 22, 2005
September 22, 2016
August 1999
November 2006   (Final data collection date for primary outcome measure)
Survival without pericardial effusion at 2 months
Same as current
Complete list of historical versions of study NCT00132613 on ClinicalTrials.gov Archive Site
  • Successful extubation of pericardial drainage tube
  • time to extubation
  • survival without pericardial effusion at 1, 2, 4, 6, 12 months
  • symptom palliation
  • complication
  • long-term (> 6 months) effect on cardiac function
Same as current
Not Provided
Not Provided
Trial of Drainage With or Without Bleomycin Instillation for Malignant Pericardial Effusion
A Randomized Controlled Trial to Evaluate the Efficacy of Intra-pericardial Instillation of a Sclerosing Agent After Pericardial Drainage in Patients With Malignant Pericardial Effusion Associated With Lung Cancer (JCOG9811)
The purpose of this study is to evaluate the efficacy of pericardial instillation of bleomycin as a sclerosing agent after pericardial drainage for lung cancer-associated malignant pericardial effusion.

Malignant pericardial effusions (MPEs), which are commonly associated with cardiac tamponade, make oncologic emergencies requiring prompt drainage. In lung cancer patients, MPE is one of the most unpleasant terminal events. Drainage usually results in prompt palliation of symptoms, but recurrent effusions often occur. Sclerosis with pericardial instillation of various agents is reported to prevent the recurrence, and bleomycin is the most commonly used drug, with fewer toxicities compared with others. There is, however, no prospective trial of pericardial sclerosis as compared with drainage alone for MPEs, and it is far from clear whether sclerosis really benefits these patients in terminal stages.

Comparison: Intra-pericardial instillation of bleomycin after pericardial drainage versus drainage alone for MPEs caused by lung cancer.

Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Malignant Pericardial Effusion
  • Procedure: Observation alone after pericardial drainage
  • Drug: Pericardial instillation of bleomycin after drainage
  • Active Comparator: 1
    Procedure/Surgery: Observation alone after pericardial drainage
    Intervention: Procedure: Observation alone after pericardial drainage
  • Experimental: 2
    Drug: Pericardial instillation of bleomycin after drainage
    Intervention: Drug: Pericardial instillation of bleomycin after drainage
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
November 2006
November 2006   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Pathologically documented lung cancer
  • Clinically stable condition after pericardial drainage for malignant pericardial effusion (not necessary that it be documented by cytology)
  • Expected to live 6 weeks or longer
  • Sufficient organ function
  • Signed informed consent

Exclusion Criteria:

  • Myocardial infarction or unstable angina within 3 months
  • Constrictive pericarditis
  • Active pneumonitis
  • Severe infection or disseminated intravascular coagulation (DIC)
  • Other severe co-morbidity which could not be relieved with pericardial drainage
  • Chemotherapy-naive small cell lung cancer
Sexes Eligible for Study: All
up to 75 Years   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Tomohide Tamura , MD, Japan Clinical Oncology Group
Japan Clinical Oncology Group
Ministry of Health, Labour and Welfare, Japan
Study Chair: Tomohide Tamura, MD National Cancer Center Hospital
Japan Clinical Oncology Group
September 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP